Lexington, MA, United States
Lexington, MA, United States

Time filter

Source Type

Patent
Synageva Biopharma Corporation | Date: 2016-01-27

The present invention discloses a recombinant human N-glycosylated lysosomal acid lipase, and provides treating LAL deficiency (e.g. Wolmans disease, CESD) comprising administering to a mammal a therapeutically effective amount of said lysosomal acid lipase


Patent
Synageva Biopharma Corporation | Date: 2015-09-11

The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.


Patent
Synageva Biopharma Corporation | Date: 2014-10-06

The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.


Patent
Synageva Biopharma Corporation | Date: 2015-04-21

This disclosure relates to inexpensive and efficient methods of preparing egg white (e.g., obtained from eggs laid by transgenic chickens) for bulk chromatographic isolation of proteins (e.g., recombinant proteins) from the egg white, as well as methods of filtering acidified egg white and methods of isolating proteins from the egg white.


The present invention relates to a method for producing transgenic chickens obtained from long-term cultures of avian PGCs. Also described are techniques to produce said PGCs and transgenic birds derived from prolonged PGC cultures. These PGCs can be transfected with genetic constructs to modify the DNA of the PGC, specifically to introduce a transgene encoding an exogenous protein. When combined with a host avian embryo by known procedures, those modified PGCs are transmitted through the germ line to yield transgenic offspring. Also described are compositions comprising long-term cultures of PGCs that can be genetically modified by gene targeting, that can accept large amounts of foreign DNA and that contribute to the germline of recipient embryos.


Patent
Synageva Biopharma Corporation | Date: 2014-01-24

The present invention is long-term cultures of avian PGCs and techniques to produce germline chimeric and transgenic birds derived from prolonged PGC cultures. In some embodiments, these PGCs can be transfected with genetic constructs to modify the DNA of the PGC, specifically to introduce a transgene encoding an exogenous protein. When combined with a host avian embryo by known procedures, those modified PGCs are transmitted through the germline to yield transgenic offspring. These germline chimeric birds do not have substantial contributions of PGC-derived phenotypes in somatic cells or tissues. This invention includes compositions comprising long-term cultures of PGCs that can be genetically modified by gene targeting, that can accept large amounts of foreign DNA and that contribute to the germline of recipient embryos.


Patent
Synageva Biopharma Corporation | Date: 2014-07-17

The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produces in a transgenic avian. The antibody molecules have a heavy chain and a light chain and exhibit an increased level of antibody-dependent cell-mediated cytotoxicity (ADCC) as compared to that of anti-CD20 antibody molecules produced by CHO cells.


Patent
Synageva Biopharma Corporation | Date: 2016-04-29

The invention relates to transgenic birds capable of producing chimeric immunoglobulins, with a combination of human and avian sequence, in their B cells. In some embodiments, the birds are chickens. When challenged with an antigen, the transgenic avians produce antigen-specific functional antibodies. The invention also relates to light chain immunoglobulin transgenes for making such transgenic avians, as well as methods and vectors for disrupting endogenous immunoglobulin loci in birds.


Patent
Synageva Biopharma Corporation | Date: 2014-09-19

The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.


Patent
Synageva Biopharma Corporation | Date: 2015-04-01

Facilities, methods, and systems to produce therapeutic protein(s) can include collecting eggs from transgenic avian in a production unit in a building; transferring the eggs to a harvesting unit in the building; and harvesting egg white or egg yolk from the eggs in the harvesting unit.

Loading Synageva Biopharma Corporation collaborators
Loading Synageva Biopharma Corporation collaborators